Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BeiGene Ltd

688235
Current price
179.88 CNY +2.25 CNY (+1.27%)
Last closed 202.73 USD
ISIN US07725L1026
Sector Healthcare
Industry Biotechnology
Exchange Shanghai Stock Exchange
Capitalization 22 852 530 176 USD
Yield for 12 month +3.30 %
1Y
3Y
5Y
10Y
15Y
688235
21.11.2021 - 28.11.2021

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Address: 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

274.08 USD

P/E ratio

Dividend Yield

Current Year

+2 458 779 000 USD

Last Year

+1 415 921 000 USD

Current Quarter

+929 166 000 USD

Last Quarter

+751 652 000 USD

Current Year

+1 994 923 000 USD

Last Year

-511 062 000 USD

Current Quarter

+767 280 000 USD

Last Quarter

+626 717 000 USD

Key Figures 688235

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -795 990 016 USD
Operating Margin TTM -11.53 %
PE Ratio
Return On Assets TTM -9.69 %
PEG Ratio
Return On Equity TTM -14.62 %
Wall Street Target Price 274.08 USD
Revenue TTM 3 096 535 040 USD
Book Value 31.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 56.1 %
Dividend Yield
Gross Profit TTM -511 062 000 USD
Earnings per share -4.94 USD
Diluted Eps TTM -4.94 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -16.91 %

Dividend Analytics 688235

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 688235

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 688235

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1111.1111
Enterprise Value Revenue 6.8947
Price Sales TTM 7.38
Enterprise Value EBITDA -11.9104
Price Book MRQ 6.4453

Financials 688235

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 688235

For 52 weeks

126.97 USD 248.16 USD
50 Day MA 211.64 USD
Shares Short Prior Month 1 986 584
200 Day MA 171.7 USD
Short Ratio 4.2
Shares Short 1 510 323
Short Percent 2.91 %